137 related articles for article (PubMed ID: 31504249)
1. Applied electric fields suppress osimertinib-induced cytotoxicity via inhibiting FOXO3a nuclear translocation through AKT activation.
Li L; Hu C; Lu C; Zhang K; Han R; Lin C; Zhao S; A C; Cheng C; Zhao M; He Y
Carcinogenesis; 2020 Jul; 41(5):600-610. PubMed ID: 31504249
[TBL] [Abstract][Full Text] [Related]
2. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
[TBL] [Abstract][Full Text] [Related]
3. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
4. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
5. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
7. Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling.
Lai L; Shen Q; Wang Y; Chen L; Lai J; Wu Z; Jiang H
Toxicol Appl Pharmacol; 2021 May; 419():115518. PubMed ID: 33812963
[TBL] [Abstract][Full Text] [Related]
8. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun SY
Oncogene; 2021 Dec; 40(49):6653-6665. PubMed ID: 34635799
[TBL] [Abstract][Full Text] [Related]
9. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.
Zhang Z; Zhang M; Liu H; Yin W
J Cell Biochem; 2019 Jan; 120(1):756-767. PubMed ID: 30145802
[TBL] [Abstract][Full Text] [Related]
10. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
[TBL] [Abstract][Full Text] [Related]
11. Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N; Miyake N; Ochi N; Yamane H; Takeyama M; Nagasaki Y; Ikeda T; Yokota E; Fukazawa T; Nakanishi H; Harada D; Kiura K; Takigawa N
Exp Cell Res; 2021 Dec; 409(2):112940. PubMed ID: 34808132
[TBL] [Abstract][Full Text] [Related]
12. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
13. Fluid shear stress suppresses TNF-α-induced apoptosis in MC3T3-E1 cells: Involvement of ERK5-AKT-FoxO3a-Bim/FasL signaling pathways.
Bin G; Bo Z; Jing W; Jin J; Xiaoyi T; Cong C; Liping A; Jinglin M; Cuifang W; Yonggang C; Yayi X
Exp Cell Res; 2016 May; 343(2):208-217. PubMed ID: 27060196
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT activation attenuates acute kidney injury following liver transplantation by inducing FoxO3a nuclear export and deacetylation.
Meng F; Zhang Z; Chen C; Liu Y; Yuan D; Hei Z; Luo G
Life Sci; 2021 May; 272():119119. PubMed ID: 33508296
[TBL] [Abstract][Full Text] [Related]
15. Nuclear forkhead box O3a accumulation contributing to the proliferative suppression in liver cancer cells by PI3K/Akt signaling pathway.
Hou Y; Sun G; Jiang X; Zhu Z; Yang J
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1124-S1128. PubMed ID: 30539857
[TBL] [Abstract][Full Text] [Related]
16. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
17. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
Liu H; Yin J; Wang C; Gu Y; Deng M; He Z
Anticancer Drugs; 2014 Sep; 25(8):898-907. PubMed ID: 24814195
[TBL] [Abstract][Full Text] [Related]
18. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
